Comparing the current results to its competitors, Skye Bioscience Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.08 %, recorded in the same quarter.
Skye Bioscience Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 2.92 %
Skye Bioscience Inc 's Comment on Competition and Industry Peers
The biopharmaceutical and pharmaceutical industries are characterized by intense competition and rapid technological advancements. Competition factors include product efficacy, safety, reliability, availability, price, patent status, and timing of market introduction. Success relies on the speed of development, clinical trials, regulatory approvals, manufacturing capabilities, product differentiation, qualified personnel, patent protection, proprietary products or processes, and capital resources. The company competes with major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and public and private research organizations. If approved, nimacimab will compete with existing therapies, marketed drugs, drugs in development, and other pharmaceutical and therapeutic approaches.
November 14, 2024
In an impressive leap towards addressing the growing global obesity epidemic, Skye Bioscience, Inc. (Nasdaq: SKYE) has announced that it has surpassed the 50% patient enrollment mark in its Phase 2 clinical study known as CBeyond. The trial, which evaluates nimacimab a differentiated CB1 inhibitor aims to transform treatment options for individuals struggling with obesity and overweight conditions.Skye Bioscience, a clinical-stage biopharmaceutical company based in San Diego, has positioned itself at the forefront of metabolic health advancements. With this Phase 2 trial, they are not just focusing on symptomatic relief, but are actively working to manipulate the endocannabinoid system in a novel way, aspiri...
August 22, 2024
In an exciting development in the field of obesity treatment, Skye Bioscience has announced the launch of its Phase 2 clinical trial, known as the CBeyond trial, to evaluate the efficacy and safety of its innovative CB1 inhibitor, nimacimab. This clinical trial aims to address one of the most pressing health concerns globally: obesity, which affects millions of individuals and significantly increases the risk of various comorbidities, including cardiovascular disease, diabetes, and certain cancers.The CBeyond trial will not only assess nimacimab’s ability to safely induce weight loss on its own but will also explore the potential benefits of combining nimacimab with a GLP-1 (glucagon-like peptide-1) recept...
July 24, 2024
In a compelling virtual Key Opinion Leader (KOL) event, Skye Bioscience recently unveiled comprehensive insights into their innovative work on metabolic rewiring via CB1 inhibition. Central to the event was the detailed discussion on the upcoming Phase 2 clinical trial for Nimacimab, alongside their new collaboration with Beacon Biosignals aimed at evaluating the potential impact of Nimacimab on sleep quality and obstructive sleep apnea (OSA). A Deeper Dive into CB1 Inhibition and Metabolic RewiringThe KOL event opened with an in-depth exploration of CB1 receptor inhibition’s role in metabolic rewiring. CB1 receptors are predominantly found in the central nervous system and are involved in a variety of phy...
June 10, 2024
Skye Bioscience Shifts Focus Amidst Mixed Results in Ophthalmic Emulsion Trials and Announces Presence at ARVO 2024 Annual Meeting Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel therapeutic drugs targeting the endocannabinoid system, is navigating a pivotal phase in its clinical development strategy. Recently, Skye Bioscience announced two major developments: the discontinuation of its SBI-100 Ophthalmic Emulsion program following its Phase 2a trial and renewed focus on its promising Nimacimab Metabolic Program. Additionally, the company affirmed its participation in the upcoming Association for Research in ...
Alcon Inc's business model revolves around providing advanced eye care products and services, including pharmaceuticals, surgical equipment, and vision care solutions.
Cannapharmarx Inc operates on a business model centered around the production and distribution of pharmaceutical products derived from cannabis. They aim to leverage the medicinal properties of cannabis to develop innovative treatment options for various medical conditions. Their model involves extensive research and development, strategic partnerships, and adherence to strict regulatory guidelines for the safe and effective delivery of their products.
Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for inflammatory and fibrotic diseases. Their business model revolves around conducting research and clinical trials to identify potential drug candidates, obtaining regulatory approvals, and subsequently commercializing these drugs to generate revenue. They aim to address unmet medical needs by creating and marketing novel treatments for diseases such as systemic sclerosis, cystic fibrosis, and other inflammatory conditions.
Cv Sciences Inc operates through a business model focused on the production and sale of cannabidiol (CBD) based products. The company sources hemp for extraction, processes it into various CBD products, and distributes them through multiple channels, including online sales and retail partnerships. By leveraging the growing demand for CBD, Cv Sciences Inc aims to generate revenue and establish a market presence in the emerging health and wellness industry.
Enveric Biosciences Inc's business model centers around the development and commercialization of innovative cannabinoid medicines and therapies to address various medical conditions, primarily focusing on cancer-related symptoms and improving patient outcomes. The company aims to leverage its expertise in the pharmaceutical industry to advance its pipeline, obtain regulatory approvals, and establish strategic partnerships for the distribution and sale of its products.
Sources:
Skye Bioscience Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Skye Bioscience Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
